Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Vir Biotechnology Inc. VIR

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue.


Recent & Breaking News (NDAQ:VIR)

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire 44 minutes ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 21, 2022

Vir Biotechnology Announces Transition of Chief Scientific Officer

GlobeNewswire July 14, 2022

Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

GlobeNewswire June 25, 2022

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress(TM) 2022

GlobeNewswire June 8, 2022

Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details

GlobeNewswire May 18, 2022

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 5, 2022

Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day

GlobeNewswire April 27, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR

PR Newswire April 23, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vir Biotechnology, Inc. - VIR

Newsfile April 21, 2022

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022

GlobeNewswire April 21, 2022

Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day

GlobeNewswire April 13, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR

PR Newswire April 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR

Newsfile April 9, 2022

Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge

GlobeNewswire April 6, 2022

Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference

GlobeNewswire April 4, 2022

Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600

PR Newswire March 29, 2022

US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant

GlobeNewswire March 25, 2022

Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference

GlobeNewswire March 2, 2022

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 24, 2022